CAJ | 학술논문

目的：评价艾地苯醌治疗缺血性脑卒中后抑郁的临床疗效和安全性。方法将64例脑梗死后抑郁患者随机分成对照组和艾地苯醌组各32例，对照组给予神经内科常规治疗及心理治疗，艾地苯醌组在此基础上加用艾地苯醌。分别于治疗前、治疗后4周对2组患者进行汉密尔顿抑郁量表评分（HAMD）、神经功能缺损评分（SSS）和疗效评定。结果艾地苯醌组抗抑郁疗效及神经功能康复疗效均优于对照组，差异有统计学意义（ P＜0.05）。结论艾地苯醌对缺血性脑卒中后抑郁有较好的疗效，并能促进神经功能的恢复。
목적：평개애지분곤치료결혈성뇌졸중후억욱적림상료효화안전성。방법장64례뇌경사후억욱환자수궤분성대조조화애지분곤조각32례，대조조급여신경내과상규치료급심리치료，애지분곤조재차기출상가용애지분곤。분별우치료전、치료후4주대2조환자진행한밀이돈억욱량표평분（HAMD）、신경공능결손평분（SSS）화료효평정。결과애지분곤조항억욱료효급신경공능강복료효균우우대조조，차이유통계학의의（ P＜0.05）。결론애지분곤대결혈성뇌졸중후억욱유교호적료효，병능촉진신경공능적회복。
Objective To evaluate the clinical efficacy and safety of idebenone on ischemic post-stroke depression.Methods A total of 64 patients with ischemic post-stroke depression were randomly divided into idebenone group (n=32)and control group(n=32).Patients in idebenone group received conventional treatment ,psychotherapy and idebenone administration ,while patients in control group received conventional treatment and psychotherapy only.Patients were evaluated by the HAMD and SSS before treatment ,and 4 weeks after treatment.Results After treatment ,the HAMD score of idebenone group were signif-icantly lower than that of the control group(P<0.05) and SSS also decreased significantly(P<0.05).The curative efficacy on post-stroke depression and neurological function deficit in idebenone group were better than those of control group.Conclusion Idebenone can effectively treat post-stroke depression and ameliorate the neurological function without obvious side effect.